HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
RNAZ
TransCode Therapeutics, Inc.
There isn't enough reported data to score RNAZ yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
RNAZ Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
RNAZ's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
RNAZ PE Valuation
RNAZ has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
RNAZ Forward outlook
There aren't enough analyst estimates for RNAZ to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
RNAZ Earnings Per Share
RNAZ has the edge over HIMS in the latest year-over-year earnings comparison.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
RNAZ Quarterly Revenue
RNAZ and HIMS do not have enough comparable growth data to identify a winner.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
RNAZ has the stronger cash trend. Its trailing FCF is down 34% versus its history, compared with HIMS at down 84%.
RNAZ Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$8.1M | -$5M |
| Q4 2024 | -$3.1M | +$2.5M |
| Q3 2024 | -$3.9M | -$415.1K |
| Q2 2024 | -$2.3M | +$2.1M |
| Q1 2024 | -$3.9M | +$585.4K |
| Q4 2023 | -$5.7M | -$1.6M |
| Q3 2023 | -$3.5M | +$911.6K |
| Q2 2023 | -$4.4M | -$995.6K |
RNAZ has burned cash in almost every quarter: −$22M over the past year, against −$16M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over RNAZ on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
RNAZ Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -20% | -3.2K shares |
| 1 year | +14862% | +12.6K shares |
| 3 years | +181586% | +12.7K shares |
RNAZ has 12,718 diluted shares, up 14862% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
RNAZ Net Leverage
RNAZ's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
RNAZ Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.8 | Oversold |
| Stochastic | 1.9 | Oversold |
RNAZ's weekly RSI is 29 (oversold) and its Stochastic is 2 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
RNAZ PE vs Healthcare Sector
RNAZ has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
RNAZ Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.64 | 15% below |
| 20 week MA | $3.36 | 59% below |
| 50 week MA | $6.12 | 77% below |
| 100 week MA | $19.7 | 93% below |
| 200 week MA | $25,683.4 | 100% below |
RNAZ is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over RNAZ on returns for 2026, with the stronger performance.
RNAZ Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $2,735,040.0 | $1,389,696.0 | -49% |
| 2022 | $1,389,696.0 | $187,002.8 | -87% |
| 2023 | $187,002.8 | $4,264.8 | -98% |
| 2024 | $4,264.8 | $72.0 | -98% |
| 2025 | $72.0 | $6.96 | -90% |
| 2026 YTD | $6.96 | $1.39 | -80% |
RNAZ has finished every year since 2021 lower, and it's down 80% so far in 2026.